CTRV - ContraVir Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

ContraVir Pharmaceuticals, Inc.

399 Thornall Street
First Floor
Edison, NJ 08837
United States
732-902-4000
http://www.contravir.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Mr. James R. SapirsteinCEO & Director596.64kN/A1961
Dr. Theresa MatkovitsChief Operating Officer250kN/A1967
Dr. John Z. Sullivan-BolyaiPart-Time Consultant & Member of Scientific Advisory Board320kN/A1948
Mr. John T. CavanChief Financial OfficerN/AN/A1958
Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D.Chief Scientific OfficerN/AN/A1958
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Corporate Governance

ContraVir Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.